PRA Health Sciences (PRAH) Tops Q4 EPS by 7c

PRA Health Sciences (NASDAQ: PRAH) reported Q4 EPS of $1.54, $0.07 better than the analyst estimate of $1.47. Revenue for the quarter came in at $800.2 million versus the consensus estimate of $795.56 million.

Full Year 2020 and Q1 2020 Guidance

For full year 2020, the Company expects to achieve total revenues between $3.23 billion and $3.36 billion, representing as reported and constant currency growth of 5.0% to 9.5%.

We expect GAAP net income per diluted share of between $4.01 and $4.21 per share and adjusted net income per diluted share of between $5.77 and $5.97 per share, representing growth of 12% to 15%. We anticipate an annual effective income tax rate estimate of 23%.

Our effective tax rate may differ from this estimate, due to, among other things, changes to estimates of the geographic allocation of our pre-tax income as well as changes in interpretations, analysis, and additional guidance that may be issued by regulatory agencies.

For Q1 2020, the Company expects to achieve total revenues between $765.0 million and $787.0 million, representing as reported and constant currency growth of 6% to 9%. The Company expects GAAP net income per diluted share of between $0.59 and $0.69 per share, adjusted net income per diluted share between $1.05 and $1.15 per share, and an annual effective income tax rate of 23%.

Our 2020 guidance assumes a EURO rate of 1.15 and a GBP rate of 1.30 with all other foreign currencies using a rate as of January 31, 2020.

For earnings history and earnings-related data on PRA Health Sciences (PRAH) click here.

You May Also Be Interested In

• O'Reilly Automotive (ORLY) Misses Q1 EPS by 7c, Offers Guidance
• Impinj (PI) Tops Q1 EPS by 11c, provides guidance
• Newmarket (NEU) Reports Q1 EPS of $11.23